Lundbeck, Takeda deal

Takeda and LUN will co-develop and co-commercialize two of LUN's bisarylsulphanylamines in the U.S. and Japan to treat mood and anxiety disorders. Lu AA21004, a serotonin modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD). Lu AA24530 is an undisclosed compound in Phase I testing to treat depression. Takeda also received an option to two other LUN bisarylsulphanylamines: Lu AA34893, which is in Phase I testing for depression, and an undisclosed preclinical compound. ...